EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The EBV-Positive Tumor Methylome Is Distinct from EBV-Negative in Diffuse Large B-Cell Lymphoma

Ashley K Volaric iD, Ramiro Barrantes-Reynolds iD, Karine Sahakyan, Yuri Fedoriw, Seth Frietze iD

Cancers · 13.09.2025 · 17 (18) · 2994

DOI: 10.3390/cancers17182994 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 13.09.2025. Verfasst von Ashley K Volaric und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, University of Vermont Larner College of Medicine, University of Vermont Cancer Center, Burlington, V…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Backgrounds: Epstein–Barr virus (EBV) is implicated in the pathogenesis of different B-cell lymphomas and lymphoproliferative disorders, including diffuse large B-cell lymphoma (DLBCL) arising in immunodeficiency settings. Despite its clinical significance, the mechanisms of EBV-mediated lymphomagenesis across different disease subtypes remain poorly understood. Global DNA methylation profiling can provide insight into tumor heterogeneity and disease mechanisms.

Methods

To further characterize the underlying biology of EBV(+) DLBCL, we performed a global methylome analysis of a cohort of EBV(+)/(−) DLBCL. Illumina MethylationEPIC array data were generated from a curated set of DLBCL tissue samples (n = 43) from a rural patient population with defined EBV status and immunodeficiency background. Differential methylation analyses were conducted using linear mixed models to identify significant methylation changes associated with EBV status.

Results

Principle component analysis (PCA) and probe-level comparisons revealed a distinct, globally hypermethylated DNA methylome in EBV(+) DLBCL compared to EBV(−) cases, and an overall hypomethylated profile in all DLBCL relative to control tissues. We identified a total of 117,334 differentially methylated probes mapping to 1557 cancer-associated genes in EBV(+) versus EBV(−) DLBCL, and 330,872 probes mapping to 4230 cancer-associated genes in all DLBCL versus controls. Pathway enrichment analysis highlighted distinct biological processes in EBV(+) DLBCL, including P53 feedback loops (hypermethylated genes) and MAPK signaling (hypomethylated genes).

Conclusions

These findings demonstrate that EBV(+) DLBCL is epigenetically distinct from EBV(−) disease, with alterations that may contribute to clinical heterogeneity and potentially serve as biomarkers for disease classification and therapeutic targeting.

Schlagwörter

Stichwörter der Autor:innen

DLBCLEBVEpstein–Barr virusdiffuse large B-cell lymphomaepigeneticsmethylationmethylome

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, University of Vermont Larner College of Medicine, University of Vermont Cancer Center, Burlington, VT 05401, USA.
  • Department of Microbiology and Molecular Genetics, University of Vermont, Burlington, VT 05401, USA.
  • Department of Radiology, University of Vermont Larner College of Medicine, Burlington, VT 05401, USA.
  • Department of Pathology and Laboratory Medicine, University of North Carolina Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA.
  • Department of Biomedical and Health Sciences, University of Vermont, University of Vermont Cancer Center, Burlington, VT 05401, USA.

ORCID-Profile: Ashley K Volaric, Ramiro Barrantes-Reynolds, Seth Frietze

Förderung

  • NIGMS NIH HHS
  • NIH HHS
  • National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health
  • UVM Pathology Research Support Award

Zitieren

APA

Volaric, A. K., Barrantes-Reynolds, R., Sahakyan, K., Fedoriw, Y., & Frietze, S. (2025). The EBV-Positive Tumor Methylome Is Distinct from EBV-Negative in Diffuse Large B-Cell Lymphoma. Cancers, 17(18), 2994. https://doi.org/10.3390/cancers17182994

Vancouver

Volaric AK, Barrantes-Reynolds R, Sahakyan K, Fedoriw Y, Frietze S. The EBV-Positive Tumor Methylome Is Distinct from EBV-Negative in Diffuse Large B-Cell Lymphoma. Cancers. 2025;17(18):2994. doi:10.3390/cancers17182994

BibTeX
@article{Volaric2025,
  author = {Volaric, Ashley K and Barrantes-Reynolds, Ramiro and Sahakyan, Karine and Fedoriw, Yuri and Frietze, Seth},
  title = {The EBV-Positive Tumor Methylome Is Distinct from EBV-Negative in Diffuse Large B-Cell Lymphoma},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {18},
  pages = {2994},
  doi = {10.3390/cancers17182994}
}
Kostenlos starten →